Phase 2, Randomized, Multicenter Trial of the Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
Latest Information Update: 13 Oct 2025
At a glance
- Drugs Adjuvanted plague vaccine Dynavax (Primary)
- Indications Plague
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Dynavax Technologies
Most Recent Events
- 13 Oct 2025 New trial record